Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy

Jie Mei(Sun Yat-sen University), Rong Guo(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Jingwen Zou(Sun Yat-sen University), Wen‐Ping Lin(Sun Yat-sen University), Lianghe Lu(Sun Yat-sen University), Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuqi Sun(Zhejiang University)
Journal of Inflammation Research
August 1, 2021
10.2147/jir.s325600
Cited by 49

Related Papers

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216
Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety
|癌症：英文版|2018|189
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
|European Journal of Endocrinology|2011|160